Effects of Fenofibrate Treatment on Cardiovascular Disease Risk in 9,795 Individuals With Type 2 Diabetes and Various Components of the Metabolic Syndrome: The Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study

OBJECTIVE—We explored whether cardiovascular disease (CVD) risk and the effects of fenofibrate differed in subjects with and without metabolic syndrome and according to various features of metabolic syndrome defined by the Adult Treatment Panel III (ATP III) in subjects with type 2 diabetes in the F...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Scott, Russell, O'Brien, Richard, Fulcher, Greg, Pardy, Chris, d'Emden, Michael, Tse, Dana, Taskinen, Marja-Riitta, Ehnholm, Christian, Keech, Anthony
Format: Artigo
Idioma:Inglês
Publicat: American Diabetes Association 2009
Matèries:
Cardiovascular and Metabolic Risk
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC2646035/
https://ncbi.nlm.nih.gov/pubmed/18984774
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2337/dc08-1543
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars